Liquidity and Financial Condition (Details Textual) - USD ($)			1 Months Ended	12 Months Ended
	Aug. 10, 2017	Dec. 13, 2016	Dec. 31, 2016	Sep. 30, 2017	Jul. 31, 2017	Jul. 31, 2016
Net Income (Loss) Attributable to Parent, Total					$ 6,580,613	$ (7,814,256)
Retained Earnings (Accumulated Deficit), Total					(54,604,729)	$ (61,185,342)
Working Capital					6,620,493
Net Cash Provided by (Used in) Operating Activities, Continuing Operations					5,556,162
Revenue Recognition, Milestone Method, Revenue Recognized				$ 25,000,000	20,000,000
License Agreement Amendment Description		(i) $20,625,000 and then the Residual Royalty thereafter or (ii) $26,250,000, if Adapt has received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN (the Earn Out Milestone), and then the Residual Royalty thereafter.
Residual Royalty Defined In Purchase Agreement		(i) if the Earn Out Milestone is paid, then SWK will receive 10% of all Royalties; provided, however, if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 5% of all Royalties after such date, and (ii) if the Earn Out Milestone is not paid, then SWK will receive 7.86% of all Royalties; provided, however, that if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK will receive 3.93% of all Royalties after such date.
Proceeds from Royalties Received			$ 13,710,000		17,460,000
Legal Fees		$ 40,000			40,000
SWK Purchase Agreement [Member]
Proceeds from Royalties Received					$ 13,750,000
Subsequent Event [Member]
Proceeds from Royalties Received	$ 3,750,000